Maze Therapeutics, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-08-17. Between them they name 3 people, with 1 appointment and 2 departures. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Paula A. Johnson, Director, effective 2026-08-13
On August 13, 2026, the Board of Directors (the "Board") of Maze Therapeutics, Inc. (the "Company") appointed Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, in each case effective August 13, 2026 (the "Appointment Date").
Departing: Herv Hoppenot, Director, effective 2026-08-13
Also effective August 13, 2026, Herv Hoppenot resigned from his position as a Class II director (with a term expiring at the Company's 2027 annual meeting of stockholders), subject to and conditioned upon his immediate reappointment as a Class III director, and the Board accepted Mr. Hoppenot's resignation and immediately reappointed him as a Class III director with a term expiring at the Company's 2028 annual meeting of stockholders.
Departing: Amy Bachrodt, Senior Vice President, Finance, effective 2026-06-01
On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the "Company"), effective June 1, 2026.
Find people with the same kind of experience as the Director at Maze Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Maze Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Maze Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Maze Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Maze Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.